LURBINECTEDIN IS SAFE AND ACTIVE IN RELAPSED SMALL-CELL LUNG CANCER

被引：1
|
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2020年 / 10卷 / 06期
关键词：
D O I：
10.1158/2159-8290.cd-rw2020-053
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：757 / 757
页数：1
相关论文
共 50 条
  • [41] EMERGE 402: Preliminary Real-world Characteristics and Safety of Lurbinectedin in Patients With Small-cell Lung Cancer
    Bushunow, P.
    Dakhil, S.
    Lammers, P.
    Naveh, N.
    Boccuti, A.
    Hanvesakul, R.
    Li, W.
    Migas, J.
    Slater, D.
    Badin, F.
    Halmos, B.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S145 - S146
  • [42] How safe is chemotherapy and chemoradiation in elderly patients with small-cell lung cancer?
    Janssen-Heijnen, Maryska L. G.
    LUNG CANCER MANAGEMENT, 2014, 3 (01) : 5 - 7
  • [43] Exposure-Response Analyses and Clinical Utility Index to Justify the Dosage of Lurbinectedin in Small-cell Lung Cancer
    Fernandez Teruel, C.
    Lubomirov, R.
    Fudio, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S509 - S509
  • [44] Phase 2 Basket Trial of Lurbinectedin in Small-Cell Lung Cancer (SCLC): Analysis of Efficacy by Baseline Characteristics
    Sands, J.
    Paz-Ares, L.
    Besse, B.
    Peters, S.
    Sala, M. A.
    Lopez-Vilarino, J. A.
    Fernandez, C.
    Kahatt, C.
    Zeaiter, A.
    Nieto, A.
    Siguero, M.
    Zaman, K.
    Arrondeau, J.
    Delord, J. -P.
    Martinez, M.
    Anton, A.
    Awada, A.
    Kristeleit, R.
    Olmedo, M. E.
    Rubio, M. J.
    Sarantopoulos, J.
    Mosquera-Martinez, J.
    D'Arcangelo, M.
    Santoro, A.
    Trigo, Jose M.
    Subbiah, V.
    Arrondeau, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S19 - S19
  • [45] NGR-HTNF IN COMBINATION WITH DOXORUBICIN IN RELAPSED SMALL-CELL LUNG CANCER (SCLC)
    Gregorc, V.
    Santoro, A.
    Novello, S.
    Grossi, F.
    Levra, M. Giaj
    Cavina, R.
    Vigano, M. G.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    ANNALS OF ONCOLOGY, 2010, 21 : 149 - 150
  • [46] Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer
    Schuette, Wolfgang
    Nagel, Sylke
    Juergens, Stefan
    Bork, Ines
    Wollschlaeger, Bettina
    Schaedlich, Steffen
    Blankenburg, Thomas
    CLINICAL LUNG CANCER, 2005, 7 (02) : 133 - 137
  • [47] Topotecan therapy in patients with relapsed small-cell lung cancer and poor performance status
    Lilenbaum, Rogerio C.
    Huber, Rudolf M.
    Treat, Joseph
    Masters, Gregory
    Kaubitzsch, Sabine
    Lane, Stephen
    Wissel, Paul
    CLINICAL LUNG CANCER, 2006, 8 (02) : 130 - 134
  • [48] Retrospective analysis of efficacy and safety of amrubicin in refractory and relapsed small-cell lung cancer
    Shimokawa, Tsuneo
    Shibuya, Masahiko
    Kitamura, Kazuhiro
    Hosomi, Yukio
    Hibino, Suguru
    Ota, Tomohiro
    Iguchi, Mari
    Okamura, Tatsuru
    Gemma, Akihiko
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2009, 14 (01) : 63 - 69
  • [49] Treatment strategy for patients with relapsed small-cell lung cancer: past, present and future
    Wakuda, Kazushige
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (02) : 172 - 179
  • [50] Lower optimal dose of amrubicin for relapsed small-cell lung cancer: a retrospective study
    Shinji Nakamichi
    Kaoru Kubota
    Fenfei Zou
    Anna Hayashi
    Natsuki Takano
    Naomi Onda
    Masaru Matsumoto
    Akihiko Miyanaga
    Rintaro Noro
    Masahiro Seike
    International Journal of Clinical Oncology, 2023, 28 : 872 - 879
12345